JNJ Johnson & Johnson

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model not detailed; filing focuses on corporate governance and compliance policies
• • New emphasis on transparency with online posting of Code of Business Conduct amendments and waivers within five business days
• • Strengthened insider trading policy for directors, officers, and certain insiders to ensure compliance with laws and listing standards
• • No financial or operational metrics disclosed in the Business section for fiscal year 2026
• • Unusual focus on detailed disclosure of corporate governance codes and ethical standards rather than product or market information

Management Discussion & Analysis

• • Revenue $94.2B in 2025, up 6.0% YoY from $88.8B in 2024; U.S. sales $53.8B (+6.9%), international $40.4B (+5.0%)
• • Operating margin 34.6% in 2025 vs 18.8% in 2024; Innovative Medicine margin 36.9% vs 33.2%; MedTech margin 12.2% vs 11.7%
• • Best segment: Innovative Medicine sales $60.4B (+6.0%), worst: Infectious Diseases sales $3.2B (-4.6%)
• • Cash/cash equivalents $20.1B end 2025; total debt $47.9B; acquisitions funded with senior notes; restructuring costs $205M (Surgery), $307M (Orthopaedics)
• • Risks: biosimilar competition impacting STELARA; expected generic competition for OPSUMIT in 2026; planned Orthopaedics separation in 18-24 months

Risk Factors

• • Board Regulatory Compliance & Sustainability Committee oversees cybersecurity risk and compliance with privacy laws
• • CISO provides quarterly updates on evolving cybersecurity threats and incidents impacting the company and industry
• • CIO and CISO responsible for cybersecurity incident detection, response, and recovery with 25+ years CISO experience
• • Cybersecurity risk management integrated into overall risk framework, with emphasis on threats relevant to 2026 landscape

What are the latest JNJ SEC filings in 2026?

Johnson & Johnson (JNJ) has filed a 10-K annual report on February 11, 2026, a 10-Q quarterly report on April 22, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did JNJ file its most recent 10-K annual report?

Johnson & Johnson (JNJ) filed its most recent 10-K annual report on February 11, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view JNJ 10-Q quarterly reports?

Johnson & Johnson (JNJ)'s most recent 10-Q quarterly report was filed on April 22, 2026. SignalX displays every JNJ 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has JNJ filed recently?

Johnson & Johnson (JNJ)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find JNJ insider trading activity (Form 4)?

The most recent JNJ Form 4 insider transaction on SignalX was filed on December 1, 2025. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock. SignalX aggregates every JNJ Form 4 with transaction code, share count, and price per share.

How often does JNJ file with the SEC?

Johnson & Johnson (JNJ) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new JNJ filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Johnson & Johnson (JNJ).

What is JNJ's SEC CIK number?

Johnson & Johnson (JNJ)'s SEC CIK (Central Index Key) number is 200406. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 200406 to look up all JNJ filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find JNJ return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Johnson & Johnson (JNJ) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.